CME Presentations

Prostate Cancer


Presentations


Speakers


CME Information

2nd Annual Virtual Summit: Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer


Global LogoPQH Logo

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

Session One: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients
  • Review the rationale behind biomarker testing in prostate cancer to assess patients’ risk and prognosis and determine treatment
  • Discuss how molecular testing in patients with prostate cancer can guide treatment selection
  • Review the recent recommendations by NCCN, AUA, and ASCO regarding molecular testing in patients with prostate cancer
  • Implement physician-patient communication strategies to inform and counsel patients with prostate cancer about molecular testing
Session Two: Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
  • Evaluate when to initiate antiandrogen therapy in asymptomatic nmCRPC patients with a rising PSA
  • Assess the new and emerging clinical evidence from practice-changing clinical trials for treatment strategies in nmCRPC
  • Review the approaches to mitigating side effects associated with antiandrogen therapy for patients with nmCRPC
Session Three: Optimizing Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Evaluate existing and emerging therapeutic options for patients with mCRPC
  • Select optimal therapies for patients with mCRPC with and without visceral metastases
  • Review novel emerging treatment strategies that are currently being investigated in phase III clinical trials of prostate cancer
Session Four: PARP Inhibition: A New Paradigm in Prostate Cancer Care
  • Review the role of PARP inhibitors in prostate cancer treatment and hot to mitigate adverse events associated with this therapy
  • Address misconceptions of patients who may not recognize the utility of PARP inhibitors in the treatment of prostate cancer
These activities are jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Large Urology Group Practice Association (LUGPA).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Advanced Accelerator Applications USA, Inc., Astellas and Pfizer Inc., Clovis Oncology, Inc., Dendreon, Exact Sciences, Myriad Genetics, and Sanofi Genzyme.

TARGET AUDIENCE

The educational design of this activity addresses the needs of medical oncologists, radiation oncologists, urologists, nuclear medicine, nurses, pharmacists, and advanced practice providers involved in the management of patients with prostate cancer.

STATEMENT OF NEED/PROGRAM OVERVIEW

Prostate cancer is the second-leading cause of death in men in the United States. However, new evidence-based treatment strategies for metastatic and nonmetastatic disease, novel targeted therapies, and predictive and prognostic biomarkers are allowing clinicians to treat patients who were previously considered untreatable.

In order to take full advantage of these improvements in the care of patients with prostate cancer, join moderator Neal Shore, MD, FACS; the Large Urology Group Practice Association; and your fellow urology/oncology professionals for the Second Annual Virtual Summit on Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer.

Providing real-time interactions and convenience to busy clinicians, the 4-part online summit includes a combination of live and on-demand sessions designed to explore the use of biomarker testing to assess disease risk, new and emerging therapeutic options, treatment-related adverse events, and strategies for selecting the most appropriate treatment for each patient.

Session 1 (on-demand): “Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients,” will examine the role of biomarkers in predicting patients’ risk for prostate cancer and prognosis to determine the optimal treatment choice.

Session 2 (live and on-demand): “Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC),” will explore the diagnosis of nmCRPC, updates to the evidence-based guidelines for its treatment, and the latest clinical data on antiandrogen agents.

Session 3 (live and on-demand): “Optimizing Treatment for Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC),” will review strategies for risk stratification of patients, current and emerging therapies, and the selection, initiation, monitoring, and sequencing of treatment for mCRPC.

Session 4 (on-demand): “PARP Inhibition: A New Paradigm in Prostate Cancer Care,” will take a closer look at the utility of PARP inhibitors in the treatment of prostate cancer and discuss the selection of patients who are most likely to benefit from this treatment option.

SESSION ONE: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients

Activity Overview

Session 1 (on-demand): “Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients,” will examine the role of biomarkers in predicting patients’ risk for prostate cancer and prognosis to determine the optimal treatment choice. Dr. Neal Shore and Dr. Simpa Salami will discuss the rationale for molecular testing and review updates to the recommendations from NCCN, AUA, and ASCO on the use of biomarkers. Discover strategies to improve communication with your patients and ensure they understand the utility of biomarker testing in improving their outcomes and quality of life.

DATE OF RELEASE/EXPIRATION

December 14, 2020 – December 14, 2021

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

SESSION TWO: Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

Activity Overview

Session 2 (live and on-demand): “Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC),” will review existing and emerging therapeutic strategies for patients with prostate cancer that is nonmetastatic. Dr. Neal Shore will moderate a panel with Dr. Tomasz M. Beer and Dr. Oliver Sartor, MD that explores the diagnosis of nmCRPC, updates to the evidence-based guidelines for its treatment, and the latest clinical data on antiandrogen agents. Return to your practice with a clear idea of when and how to safely and effectively initiate therapy in your patients with nmCRPC and manage side effects associated with treatment.

DATE OF RELEASE/EXPIRATION

December 14, 2020 – December 14, 2021

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

SESSION THREE: Optimizing Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Activity Overview

Session 3 (live and on-demand): “Optimizing Treatment for Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC),” will focus on metastatic prostate cancer and its management. Moderated by Dr. Neal Shore with expert panelists Dr. Tomasz M. Beer and Dr. Oliver Sartor, MD, this session will look at strategies for risk stratification of patients, along with the selection, initiation, monitoring, and sequencing of treatment for mCRPC. Data from recent practice-changing clinical trials will be examined, so that clinicians have an accurate understanding of current and emerging therapies and their places in the armamentarium to care for patients with mCRPC.

DATE OF RELEASE/EXPIRATION

December 14, 2020 – December 14, 2021

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

SESSION FOUR: PARP Inhibition: A New Paradigm in Prostate Cancer Care

Activity Overview

Session 4 (on-demand): “PARP Inhibition: A New Paradigm in Prostate Cancer Care,” will take a closer look at the utility of PARP inhibitors in the treatment of prostate cancer. Expert panelists Dr. Neal Shore and Dr. David Quinn will review the available PARP inhibitors, discuss the selection of patients who are most likely to benefit from this treatment option, and explain how to manage associated adverse events. Learn strategies to clear up common misconceptions among your patients who may be hesitant to use PARP inhibitors and convey the benefits of this treatment option when appropriate.

DATE OF RELEASE/EXPIRATION

December 14, 2020 – December 14, 2021

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for each activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for any of these educational activities.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology Clinics
Consultant/Independent Contractor: AbbVie, Ambry Genetics, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, FerGene, Ferring, Foundation Medicine, Genzyme, Invitae, Janssen, MDxHealth, Merck, Myovant Sciences, Myriad, Nymox, Pfizer, Sanofi, Tolmar
Speaker’s Bureau: Astellas, Bayer, Clovis, Janssen, Pfizer
Oliver Sartor, MD
C.E. and Bernadine Laborde Professor of Cancer Research,
Assistant Dean for Oncology,
Tulane University School of Medicine;
Medical Director,
Tulane Cancer Center
Consultant/Independent Contractor: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics
Grant/Research Support: Advanced Accelerator Applications, AstraZeneca, Bayer, Constellation, Dendreon, Endocyte, Invitae, Janssen, Merck, Progenics, Sanofi, SOTIO
Tomasz M. Beer, MD, FACP
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Deputy Director, OHSU Knight Cancer Institute
Chief Medical Officer, CEDAR
Professor of Medicine, Hematology & Medical Oncology
Director, Prostate Cancer Research Program
Oregon Health & Science University
Portland, Oregon
Consultant/Independent Contractor: Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Constellation Pharmaceuticals, GRAIL Inc., Janssen, Myovant Sciences, Novartis, Pfizer, Sanofi
Grant/Research Support: Alliance Foundation Trials, Astellas, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Freenome, GRAIL Inc., Harpoon Therapeutics, Janssen Research & Development, Medivation Inc., Sotio, Theraclone Sciences/ OncoResponse, Zenith Epigenetics
Stock Shareholder: Arvinas Inc, Salarius Pharmaceuticals
Simpa S. Salami MD, MPH
Assistant Professor of Urology
Division of Urologic Oncology
Department of Urology
University of Michigan
Ann Arbor, Michigan
Nothing to disclose
David I. Quinn MD
Associate Professor of Medicine (Clinical Scholar)
Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine
Health Sciences Campus
Los Angeles, CA
Consultant/Independent Contractor: Astellas, AstraZeneca, Bayer, EMD Serono, Janssen, Merck, Pfizer
Grant/Research Support: Genentech, Merck, Pfizer,
Honoraria: Astellas, AstraZeneca, Bayer, EMD Serono, Janssen, Merck, Pfizer
Advisory Board: Astellas, AstraZeneca, Bayer, EMD Serono, Janssen, Merck, Pfizer

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Bridget Griffin Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact UroCareLive or OMedLive at 877-394-1306 or at support@omedlive.com